284462-80-2

Usage

Uses

Used in Medicinal Chemistry:
4-(2-Carbamoyl-pyridin-4-yloxy)aniline is used as a building block for drug discovery and development. Its unique structure and functional groups make it a promising candidate for the design and synthesis of new pharmaceutical compounds.
Used in Materials Science:
4-(2-Carbamoyl-pyridin-4-yloxy)aniline may have potential applications in materials science, such as in the development of new materials with specific properties or functions. Its chemical structure and reactivity could be utilized to create novel materials with improved performance.
Used in Chemical Synthesis:
4-(2-Carbamoyl-pyridin-4-yloxy)aniline can be used as an intermediate or reactant in various chemical synthesis processes. Its versatility and reactivity make it a valuable component in the synthesis of other complex organic compounds.
Further research and testing are required to fully understand the properties and potential applications of 4-(2-Carbamoyl-pyridin-4-yloxy)aniline. Its unique structure and functional groups offer exciting opportunities for exploration and innovation in various scientific and industrial fields.

InChI:InChI=1/C12H11N3O2/c13-8-1-3-9(4-2-8)17-10-5-6-15-11(7-10)12(14)16/h1-7H,13H2,(H2,14,16)

Upstream product

• 99586-65-9 4-chloropicolinamide 
• 123-30-8 4-amino-phenol 
• 176977-85-8 methyl 4-chloropyridine-2-carboxylate hydrochloride 
• 176977-85-8 methyl 4-chloro-2-pyridinecarboxylate hydrochloride 

Downstream Products

• 220000-87-3 4-chloro-N-methylpicolinamide 
• 284461-74-1 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-2-pyridine carboxamide 
• 99586-65-9 4-chloropicolinamide 

Relevant academic research and scientific papers

ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY

This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

Aryl ureas as kinase inhibitors

This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VE

DIARYL UREAS AND COMBINATIONS

The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I) : B-NH-C(O)-NH-L-M-L1-(Q)1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. Each Q is independently C(O)R4, C(O)OR4 and C(O)NR4R5; and L' is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.

TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS

The present invention provides compositions and methods for treating cancer with sorafenib, wherein the cancer that has acquired resistance to another therapeutic agent, such as kinase inhibitors. Sorafinb can also be used to treat cancers which have become refractory to other chemotherapeutic agents .

TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS

The present invention provides compositions and methods for treating cancers ; which have acquired resistance to a KIT inhibitor by administering effective amounts of sorafenib.

DIARYL UREAS WITH KINASE INHIBITING ACTIVITY

The present invention provides methods of using aryl ureas to treat diseases and conditions associated with signal transduction pathways comprising at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. The present invention also provides compositions and methods for identifying conditions and diseases which can be modulated with compounds of the present invention. These methods facilitate the selection of subjects who can be efficiently treated with compounds of the present invention. Additionally, the invention provides methods for monitoring subjects who have been administered a compound of the present invention.

Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Aryl ureas with angiogenisis inhibiting activity

This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.